USPTO Examiner NGUYEN NGHI V - Art Unit 1653

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19245319FOOD COMPOSITION FOR REDUCING ALCOHOLIC HANGUP CONTAINING PLANT EXTRACTJune 2025August 2025Allow200NoNo
18844070METHOD FOR CHARACTERIZING INTERACTION FORCE BETWEEN LIGNIN AND CELLULASESeptember 2024March 2025Allow610YesNo
18788758SYSTEMS AND METHODS FOR CELL CULTURINGJuly 2024March 2026Allow2010NoNo
18833176METHOD OF DETERMINING GLUCOSE CONCENTRATIONJuly 2024April 2025Allow901NoNo
18734282HYBRID GEL COMPRISING PARTICULATE DECELLULARIZED TISSUEJune 2024July 2025Abandon1310NoNo
18652317MALLEABLE CONTROLLED RELEASE LOCAL ANESTHETIC WITH HEMOSTATIC COMPOSITIONMay 2024June 2025Allow1310NoNo
18636644METHOD OF PREPARING FERMENTED HERBAL EYE DROPSApril 2024July 2024Allow300NoNo
18440126TARGETING CANCER CELLS AND TISSUE USING FILAMENTOUS PLANT VIRUS PARTICLESFebruary 2024June 2025Allow1620NoNo
18480172TREATMENT OF MUCOPOLYSACCHARIDOSIS I WITH FULLY-HUMAN GLYCOSYLATED HUMAN ALPHA-L-IDURONIDASE (IDUA)October 2023December 2025Allow2630NoNo
18460217REPAIR AND/OR RECONSTRUCTION OF INVERTEBRAL DISCSSeptember 2023September 2025Allow2430NoNo
18229995BOTANICAL AND BACTERIAL EXTRACTS DISPLAYING RETINOL-LIKE ACTIVITYAugust 2023April 2025Allow2130YesNo
18209877BLOOD STORAGE CONTAINER CONTAINING AQUEOUS COMPOSITION FOR THE STORAGE OF RED BLOOD CELLSJune 2023August 2024Allow1410NoNo
18209148COMPOSITIONS AND METHODS FOR ACTIVATING NK CELLSJune 2023May 2025Abandon2310NoNo
18034460PROCESS AND COMPOSITION FOR PRODUCTION OF ORGANIC SUBMICROMETRIC PARTICLES FROM WHOLE BIOLOGICAL MATTERApril 2023December 2025Allow3210NoNo
18138285PERFORATED TISSUE GRAFTApril 2023February 2025Allow2220YesNo
18134451METHOD FOR IMPROVED SPERM CELL POPULATIONSApril 2023March 2025Allow2320NoNo
18194308METHODS AND DEVICES FOR SIMULTANEOUS OPTICAL IRRADIATION AND OSCILLATING MAGNETIC FIELD RADIATION OF A TARGETMarch 2023September 2024Abandon1710NoNo
18117320TISSUE-DERIVED SCAFFOLDING MATERIALS AND METHOD FOR TISSUE FORMATIONMarch 2023June 2025Allow2711YesNo
18173333PULMONARY ADMINISTRATION OF PYOCINS FOR TREATING BACTERIAL RESPIRATORY INFECTIONSFebruary 2023August 2024Allow1710YesNo
18011257CELL CULTURE DEVICEDecember 2022December 2025Allow3610NoNo
17982788METHODS AND ARTICLES FOR DELIVERING VIABLE CELLS INTO SOLID TISSUENovember 2022May 2024Abandon1811NoNo
17959263SYSTEMS AND METHODS FOR CULTIVATING ALGAEOctober 2022March 2024Allow1721NoNo
17952813FORMULATIONS OF BIOLOGICS FOR INTRAVESICAL INSTILLATIONSeptember 2022July 2024Abandon2201NoNo
17947798GALACTOOLIGOSACCHARIDES FOR PREVENTING INJURY AND/OR PROMOTING HEALING OF THE GASTROINTESTINAL TRACTSeptember 2022March 2024Abandon1820NoNo
17900526MEANS AND METHODS FOR VISUALIZATION OF TISSUE STRUCTURESAugust 2022May 2024Abandon2111NoNo
17881200HUMAN PLASMA-LIKE MEDIUMAugust 2022September 2024Abandon2521NoNo
17876445REPAIR AND/OR RECONSTITUTION OF INVERTEBRAL DISCSJuly 2022September 2023Abandon1310NoNo
17814541METHOD OF OPERATION UTILIZING ELECTRIC FIELD FOR PROCESSING OF BLOOD TO NEUTRALIZE PATHOGEN CELLS THEREINJuly 2022December 2025Allow4110NoNo
17858920METHODS FOR CULTURING ORGANOIDSJuly 2022March 2025Allow3341YesNo
17758405TECHNICAL METHOD FOR TREATING VITILIGO THROUGH HAIR FOLLICLE MELANOCYTE STEM CELL TRANSPLANTATIONJuly 2022October 2025Allow3910NoNo
17849389EXOSOME AND PREPARATION PROCESS AND USE THEREOFJune 2022November 2024Allow2811YesNo
17787909SUPERPARAMAGNETISM-MODIFIED AND NEUTROPHIL EXOSOME BIOMIMETIC VESICLE-BASED BIOLOGICAL PREPARATION FOR DRUG DELIVERY, AND PREPARATION METHOD THEREOFJune 2022December 2025Allow4211YesNo
17778962METHODS AND SYSTEMS FOR PRODUCING SKIN GRAFTSMay 2022February 2026Allow4421YesNo
17750874HUMAN MILK OLIGOSACCHARIDES TO PROMOTE GROWTH OF BENEFICIAL BACTERIAMay 2022April 2024Abandon2211NoNo
17746473CELL CULTURE MEDIA EXTENDING MATERIALS AND METHODSMay 2022November 2023Allow1820NoNo
17768587USE OF ACELLULAR ADIPOSE TISSUE EXTRACT IN PROMOTING HAIR GROWTH AND RETENTIONApril 2022September 2025Allow4111YesNo
17715326ADVANCED FUNCTIONAL BIOCOMPATIBLE FOAM USED AS A HEMOSTATIC AGENT FOR ACUTE WOUNDSApril 2022July 2025Abandon3910NoNo
17696321BIOMATERIALS DERIVED FROM TISSUE EXTRACELLULAR MATRIXMarch 2022April 2024Abandon2501NoNo
17761074ORGAN PERFUSION SYSTEM AND METHODMarch 2022October 2025Allow4311YesNo
17641774KIT AND METHODMarch 2022December 2024Allow3311NoNo
17579680FEED ADDITIVE FORMULATION AND METHODS OF MAKING AND USING THE SAMEJanuary 2022March 2025Abandon3841NoNo
17627353ORDERED PROCESSING OF BLOOD PRODUCTS TO PRODUCE THERAPEUTICALLY ACTIVE CELLSJanuary 2022July 2025Abandon4201NoNo
17576444ALGORIPHAGUS SP, BOSEA SP, BREVUNDIMONAS SP, DESULFOVIBRIO SP, MICROBACTERIUM SP, SPHINGOMONAS SP, AND VARIOVORAX SP FOR USE IN DISEASE PREVENTION AND TREATMENTJanuary 2022March 2025Abandon3831NoNo
17597606IMPROVED BUFFER FOR THE CAPACITATION OF SPERMATOZOAJanuary 2022November 2024Abandon3410NoNo
17566234HUMAN SERUM ALBUMIN IN FORMULATIONSDecember 2021March 2025Allow3930YesNo
17622396CELL CULTURE METHODS AND COMPOSITIONSDecember 2021October 2025Allow4611YesNo
17559970TREATMENT OF HEART FAILURE AND/OR POST INFARCT PATHOLOGICAL REMODELING BY EX VIVO REPROGRAMMED IMMUNE CELLSDecember 2021July 2025Allow4220NoNo
17621403PANCREAS-ON-A-CHIP AND USES THEREOFDecember 2021August 2025Abandon4411NoNo
17643464METHOD FOR PRODUCING CELL CLUSTER GROUP AND DEVICE FOR PRODUCING SAMEDecember 2021April 2025Allow4011YesNo
17540450STABILIZED TWO-PART HEMATOXYLIN SOLUTION UTILIZING pH ADJUSTMENTDecember 2021August 2025Allow4441NoNo
17455466PROBIOTIC COMPOSITION INCLUDING LACTIC ACID BACTERIAL STRAINS AND USE THEREOFNovember 2021December 2023Allow2521YesNo
17609954GENERATING DORSAL FOREGUT, AND ANTERIOR DOMAIN, ENDODERM CELLSNovember 2021June 2025Allow4311NoNo
17607758COSMETIC COMPOSITION COMPRISING CULTURE SOLUTION OF MESENCHYMAL STEM CELLS CULTURED IN HPL-CONTAINING MEDIUMOctober 2021May 2025Allow4211YesNo
17606990COMPOSITIONS AND METHODS FOR THE TREATMENT OF RETINAL DEGENERATIONOctober 2021June 2025Abandon4411NoNo
17505688CELLULAR CULTURE MEDIUM FREE FROM SERUMOctober 2021May 2023Abandon1910NoNo
17604369USE OF A CYTOFLUOROMETRY METHOD FOR EVALUATING THE STABILITY AND VIABILITY OF A BIOMASS OF FREEZE-DRIED BACTERIAL CELLSOctober 2021August 2025Allow4620YesNo
17599895CAPSULE COMPRISING INSULIN-SECRETING CELLS FOR TREATING DIABETESSeptember 2021June 2025Abandon4521NoNo
17599458MATRIX COMPOSITIONSeptember 2021June 2025Allow4411YesNo
17442405CELL POPULATION INCLUDING PLURIPOTENT STEM CELLS AND PRODUCTION METHOD THEREOFSeptember 2021June 2025Abandon4520YesNo
17477720LACTOBACILLUS PLANTARUM HG-23 AND APPLICATION THEREOFSeptember 2021January 2024Abandon2821NoNo
17439277METHOD FOR MANUFACTURING LUMINAL STRUCTURESeptember 2021July 2025Allow4611YesNo
17472282METHODS OF TREATING DISEASES RELATED TO NET FORMATION WITH PARENTERAL ADMINISTRATION OF POLYSIALYLATED DNASE ISeptember 2021November 2023Abandon2621NoNo
17467811PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CARTILAGE DISEASESSeptember 2021May 2023Abandon2010NoNo
17435478CULTURED TISSUE AND METHOD FOR PRODUCING SAMESeptember 2021January 2025Abandon4001NoNo
17394804Reducing or Inhibiting Ocular Damage by Hyaluronidase AdministrationAugust 2021December 2023Allow2830YesNo
17376226TISSUE HEALING AGENTJuly 2021May 2025Abandon4620NoNo
17376084QUALITY OF A CELLULAR GRAFTJuly 2021November 2024Abandon4010NoNo
17367231ANTIBIOTIC-FREE COMPOSITIONS FOR THE PREVENTION OR CONTROL OF COCCIDIOSISJuly 2021February 2023Allow2010YesNo
17365207PHARMACEUTICAL COMPOSITION OR HEALTH FOOD FOR TREATING AND/OR ALLEVIATING NERVOUS DISEASESJuly 2021August 2025Allow4930NoNo
17339254DIAGNOSIS AND MONITORING OF LIVER DISEASEJune 2021May 2025Abandon4721NoYes
17332461SYNTHETIC ATTACHMENT MEDIUM FOR CELL CULTUREMay 2021March 2023Allow2210YesNo
17328517METHODS AND DEVICES FOR SIMULTANEOUS OPTICAL IRRADIATION AND OSCILLATING MAGNETIC FIELD RADIATION OF A TARGETMay 2021February 2023Allow2110NoNo
17295849METHODS FOR EXPANSION OF NATURAL KILLER (NK) CELL SUBSET AND RELATED COMPOSITIONS AND METHODSMay 2021March 2025Allow4611NoNo
17293413METHODS OF GENERATING MYCELIAL SCAFFOLDS AND APPLICATIONS THEREOFMay 2021January 2026Abandon5621NoNo
17307234COMPOSITIONS AND METHODS FOR STABILIZING SUSCEPTIBLE COMPOUNDSMay 2021February 2024Abandon3420NoNo
17250968NOVEL GRAS PROBIOTIC BACTERIAL STRAIN TO INHIBIT ACIDOSIS AND LIVER ABSCESSES IN CATTLEApril 2021July 2025Abandon5221NoNo
17221750Reducing or Inhibiting Ocular Damage by Hyaluronidase AdministrationApril 2021December 2023Allow3220YesNo
17282065CELL CULTURE TOOL AND METHOD FOR PRODUCING CELL CULTURE TOOLApril 2021June 2025Allow5121NoNo
17280702METHODS OF HUMAN RETINAL PROGENITOR CELL ISOLATION AND CULTUREMarch 2021May 2025Allow4920NoYes
17268854PROCESS FOR PURIFYING AN ANTIBODY FROM EGG YOLK, PRODUCTS AND USES THEREOFFebruary 2021April 2025Allow5030NoNo
17165523HOST-GUEST METAL ORGANIC FRAMEWORK SYSTEMSFebruary 2021September 2023Allow3220YesNo
17160090APPLICATION OF PHLEGMYHEATCLEAR IN PREPARATION OF DRUG FOR TREATMENT OF ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASEJanuary 2021January 2024Abandon3640NoNo
17261533SOLUBILIZED APYRASES, METHODS AND USEJanuary 2021September 2024Allow4311NoNo
17259644HALOPEROXIDASE COMPOSITIONS AND USES THEREOFJanuary 2021November 2023Abandon3510NoNo
17259161Method For Extracting And Isolating Lutein Crystal From Vegetable Oil Resin Containing Lutein DiesterJanuary 2021November 2023Allow3410NoNo
17137933NOVEL APPLICATION OF HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR FOR MEDICAL PURPOSESDecember 2020July 2024Abandon4210NoNo
17256383IMMUNOMODULATORY COMPOSITIONS AND USES THEREOFDecember 2020September 2024Abandon4401NoNo
17251155COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONSDecember 2020December 2024Abandon4931NoNo
17058991METHOD FOR ENRICHING AND SEPARATING ANAEROBIC FIBER-DEGRADING BACTERIUM ON THE BASIS OF CELLULOSIC MAGNETIC NANOPARTICLESNovember 2020April 2024Allow4111YesNo
17057500METHODS OF SELECTING SUBJECTS FOR TREATMENT WITH METABOLOMIC MODULATORSNovember 2020February 2025Allow5121YesNo
17056724USE OF 3D-PRINTED FREESTANDING STRUCTURES FOR EX VIVO TISSUENovember 2020March 2026Allow6031YesNo
17055678EXPANSION CULTURE METHOD FOR HUMAN-DERIVED NATURAL KILLER CELLS BY USING HDAC INHIBITORNovember 2020April 2025Allow5330NoNo
17090401Multi-Dimensional Biomaterial and Method for Producing the SameNovember 2020February 2024Allow3911YesNo
17080018DICARBOXYLIC ACIDS AND CORRELATED COMPOUNDS AS A MEASURE OF RED BLOOD CELL QUALITYOctober 2020February 2023Allow2810NoNo
17074902SYSTEMS AND METHODS FOR CELL CULTURINGOctober 2020May 2024Allow4381NoNo
17067560COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONSOctober 2020November 2023Abandon3710NoNo
17066162HERPES SIMPLEX VIRUS (HSV) ANTICANCER THERAPIESOctober 2020July 2023Abandon3401NoNo
17040881COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE AND FUSOBACTERIA-CAUSED OR RELATED DISEASES AND CONDITIONSSeptember 2020April 2025Abandon5421NoYes
16981995METHODS AND COMPOSITIONS COMPRISING NEMATODE SIGNALLING COMPOUNDSSeptember 2020March 2024Allow4221NoNo
16980889METHOD FOR ISOLATING AND CULTURING NEURAL STEM CELLS WITH HIGH EFFICIENCYSeptember 2020October 2024Allow4930NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NGUYEN, NGHI V.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
15
Examiner Affirmed
8
(53.3%)
Examiner Reversed
7
(46.7%)
Reversal Percentile
68.8%
Higher than average

What This Means

With a 46.7% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
51
Allowed After Appeal Filing
7
(13.7%)
Not Allowed After Appeal Filing
44
(86.3%)
Filing Benefit Percentile
16.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 13.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner NGUYEN, NGHI V - Prosecution Strategy Guide

Executive Summary

Examiner NGUYEN, NGHI V works in Art Unit 1653 and has examined 468 patent applications in our dataset. With an allowance rate of 52.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.

Allowance Patterns

Examiner NGUYEN, NGHI V's allowance rate of 52.1% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by NGUYEN, NGHI V receive 2.97 office actions before reaching final disposition. This places the examiner in the 86% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by NGUYEN, NGHI V is 40 months. This places the examiner in the 23% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +53.3% benefit to allowance rate for applications examined by NGUYEN, NGHI V. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 16.0% of applications are subsequently allowed. This success rate is in the 12% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 16.0% of cases where such amendments are filed. This entry rate is in the 18% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 26.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 30% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 58.3% of appeals filed. This is in the 32% percentile among all examiners. Of these withdrawals, 47.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 78.0% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.6% of allowed cases (in the 63% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.8% of allowed cases (in the 59% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.